<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36311179</PMID><DateRevised><Year>2022</Year><Month>11</Month><Day>02</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2052-8817</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Acute medicine &amp; surgery</Title><ISOAbbreviation>Acute Med Surg</ISOAbbreviation></Journal><ArticleTitle>Residual persistence of cytotoxicity lymphocytes and regulatory T cells in patients with severe coronavirus disease 2019 over a 1-year recovery process.</ArticleTitle><Pagination><StartPage>e803</StartPage><MedlinePgn>e803</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e803</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/ams2.803</ELocationID><Abstract><AbstractText Label="AIM" NlmCategory="UNASSIGNED">To clarify the immune cellular changes in critically ill patients recovering from coronavirus disease 2019 (COVID-19).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">The immune response of peripheral blood mononuclear cells from patients with severe COVID-19 in different stages of recovery (3, 6, and 12&#x2009;months from hospitalization) was evaluated by single-cell mass cytometry. Immunological changes in patients were compared with those in age-matched healthy donors.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Three patients with severe COVID-19 were compared with four healthy donors. In the patients, there was an increase in the cell density of CD4- and CD8-positive T lymphocytes, and B cells, over the course of the recovery period. CD4- and CD8-positive T lymphocytes expressing T-bet and granzyme B (Gzm B) in patients were abundant during all recovery periods. The level of regulatory T cells remained high throughout the year. The levels of natural killer (NK) cells in patients were higher than in those in the healthy donors, and the frequency of CD16<sup>+</sup> NK cells expressing Gzm B increased throughout the year.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Patients recovering from severe COVID-19 showed persistence of cytotoxic lymphocytes, NK cells, and regulatory T cells throughout the posthospitalization year of recovery.</AbstractText><CopyrightInformation>&#xa9; 2022 The Authors. Acute Medicine &amp; Surgery published by John Wiley &amp; Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mitsuyama</LastName><ForeName>Yumi</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-6272-6910</Identifier><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care Osaka General Medical Center Osaka Japan.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Traumatology and Acute Critical Medicine Osaka University Graduate School of Medicine Osaka Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yamakawa</LastName><ForeName>Kazuma</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0003-2999-4021</Identifier><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kayano</LastName><ForeName>Katsuhide</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Emergency and Critical Care Medicine Osaka Medical and Pharmaceutical University Takatsuki Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maruyama</LastName><ForeName>Miho</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care Osaka General Medical Center Osaka Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umemura</LastName><ForeName>Yutaka</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8357-0313</Identifier><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care Osaka General Medical Center Osaka Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wada</LastName><ForeName>Takeshi</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0001-5220-3342</Identifier><AffiliationInfo><Affiliation>Division of Acute and Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine Hokkaido University Faculty of Medicine Sapporo Japan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fujimi</LastName><ForeName>Satoshi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Trauma and Surgical Critical Care Osaka General Medical Center Osaka Japan.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Acute Med Surg</MedlineTA><NlmUniqueID>101635464</NlmUniqueID><ISSNLinking>2052-8817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CD4</Keyword><Keyword MajorTopicYN="N">CD8</Keyword><Keyword MajorTopicYN="N">CyTOF</Keyword><Keyword MajorTopicYN="N">NK</Keyword><Keyword MajorTopicYN="N">Treg</Keyword><Keyword MajorTopicYN="N">T&#x2010;bet</Keyword><Keyword MajorTopicYN="N">cytotoxicity</Keyword><Keyword MajorTopicYN="N">granzyme B</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>10</Month><Day>31</Day><Hour>4</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>1</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36311179</ArticleId><ArticleId IdType="pmc">PMC9597380</ArticleId><ArticleId IdType="doi">10.1002/ams2.803</ArticleId><ArticleId IdType="pii">AMS2803</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wong LR, Perlman S. Immune dysregulation and immunopathology induced by SARS&#x2010;CoV&#x2010;2 and related coronaviruses &#x2010; are we our own worst enemy? Nat. Rev. Immunol. 2022; 22: 47&#x2013;56 [published correction appears in Nat Rev Immunol 2021 Dec 17].</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8617551</ArticleId><ArticleId IdType="pubmed">34837062</ArticleId></ArticleIdList></Reference><Reference><Citation>Su Y, Yuan D, Chen DG et&#xa0;al. Multiple early factors anticipate post&#x2010;acute COVID&#x2010;19 sequelae. Cell 2022; 185: 881&#x2013;895.e20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8786632</ArticleId><ArticleId IdType="pubmed">35216672</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugiyama A, Miwata K, Kitahara Y et&#xa0;al. Long COVID occurrence in COVID&#x2010;19 survivors. Sci. Rep. 2022; 12: 6039.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8996498</ArticleId><ArticleId IdType="pubmed">35411017</ArticleId></ArticleIdList></Reference><Reference><Citation>Laboratory testing strategy recommendations for COVID&#x2010;19. Geneva: World Health Organization, 2020.</Citation></Reference><Reference><Citation>ARDS Definition Task Force , Ranieri VM, Rubenfeld GD et&#xa0;al. Acute respiratory distress syndrome: the Berlin Definition. JAMA 2012; 307: 2526&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">22797452</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit. Care Med. 1985; 13: 818&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuyama Y, Yamakawa K, Kayano K, Maruyama M, Wada T, Fujimi S. Prolonged enhancement of cytotoxic T lymphocytes in the post&#x2010;recovery state of severe COVID&#x2010;19. J. Intensive Care 2021; 9: 76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8685802</ArticleId><ArticleId IdType="pubmed">34930468</ArticleId></ArticleIdList></Reference><Reference><Citation>Zenarruzabeitia O, Astarloa&#x2010;Pando G, Terr&#xe9;n I et&#xa0;al. T cell activation, highly armed cytotoxic cells and a shift in monocytes CD300 receptors expression is characteristic of patients with severe COVID&#x2010;19. Front. Immunol. 2021; 12: 655934.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7991729</ArticleId><ArticleId IdType="pubmed">33777054</ArticleId></ArticleIdList></Reference><Reference><Citation>Meckiff BJ, Ram&#xed;rez&#x2010;Su&#xe1;stegui C, Fajardo V et&#xa0;al. Imbalance of regulatory and cytotoxic SARS&#x2010;CoV&#x2010;2&#x2010;reactive CD4+ T cells in COVID&#x2010;19. Cell 2020; 183: 1340&#x2013;1353.e16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7534589</ArticleId><ArticleId IdType="pubmed">33096020</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuwa HA, Shaw TN, Knight SB et&#xa0;al. Alterations in T and B cell function persist in convalescent COVID&#x2010;19 patients. Med. (N Y) 2021; 2: 720&#x2013;735.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8011689</ArticleId><ArticleId IdType="pubmed">33821250</ArticleId></ArticleIdList></Reference><Reference><Citation>Phetsouphanh C, Darley DR, Wilson DB et&#xa0;al. Immunological dysfunction persists for 8 months following initial mild&#x2010;to&#x2010;moderate SARS&#x2010;CoV&#x2010;2 infection. Nat. Immunol. 2022; 23: 210&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">35027728</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal&#xe1;n M, Vig&#xf3;n L, Fuertes D et&#xa0;al. Persistent overactive cytotoxic immune response in a Spanish cohort of individuals with long&#x2010;COVID: identification of diagnostic biomarkers. Front. Immunol. 2022; 13: 848886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8990790</ArticleId><ArticleId IdType="pubmed">35401523</ArticleId></ArticleIdList></Reference><Reference><Citation>Pritchard GH, Kedl RM, Hunter CA. The evolving role of T&#x2010;bet in resistance to infection. Nat. Rev. Immunol. 2019; 19: 398&#x2013;410.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7272213</ArticleId><ArticleId IdType="pubmed">30846856</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen&#x2010;driven effector CD8 T cell function regulated by T&#x2010;bet. Proc. Natl. Acad. Sci. U.S.A. 2003; 100: 15818&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC307651</ArticleId><ArticleId IdType="pubmed">14673093</ArticleId></ArticleIdList></Reference><Reference><Citation>Afonina IS, Cullen SP, Martin SJ. Cytotoxic and non&#x2010;cytotoxic roles of the CTL/NK protease granzyme B. Immunol. Rev. 2010; 235: 105&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">20536558</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmi C, Leung PS, Sherr DH et&#xa0;al. Mechanisms of environmental influence on human autoimmunity: a National Institute of Environmental Health Sciences expert panel workshop. J. Autoimmun. 2012; 39: 272&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">22749494</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao XH, He ZC, Li TY et&#xa0;al. Pathological evidence for residual SARS&#x2010;CoV&#x2010;2 in pulmonary tissues of a ready&#x2010;for&#x2010;discharge patient. Cell Res. 2020; 30: 541&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186763</ArticleId><ArticleId IdType="pubmed">32346074</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Xiao Y, Shen Y et&#xa0;al. Detection of SARS&#x2010;CoV&#x2010;2 by RT&#x2010;PCR in anal from patients who have recovered from coronavirus disease 2019. J. Med. Virol. 2020; 92: 1769&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262280</ArticleId><ArticleId IdType="pubmed">32285947</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J et&#xa0;al. Diverse functional autoantibodies in patients with COVID&#x2010;19. Nature 2021; 595: 283&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalfaoglu B, Almeida&#x2010;Santos J, Tye CA, Satou Y, Ono M. T&#x2010;cell hyperactivation and paralysis in severe COVID&#x2010;19 infection revealed by single&#x2010;cell analysis. Front. Immunol. 2020; 11: 589380.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596772</ArticleId><ArticleId IdType="pubmed">33178221</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J, Yang X, Wang H et&#xa0;al. Analysis of the long&#x2010;term impact on cellular immunity in COVID&#x2010;19&#x2010;recovered individuals reveals a profound NKT cell impairment. MBio 2021; 12: e00085&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8092197</ArticleId><ArticleId IdType="pubmed">33906918</ArticleId></ArticleIdList></Reference><Reference><Citation>Kratzer B, Trapin D, Ettel P et&#xa0;al. Immunological imprint of COVID&#x2010;19 on human peripheral blood leukocyte populations. Allergy 2021; 76: 751&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984452</ArticleId><ArticleId IdType="pubmed">33128792</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkaid Y, Tarbell K. Regulatory T cells in the control of host&#x2010;microorganism interactions (*). Annu. Rev. Immunol. 2009; 27: 551&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pubmed">19302048</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin MD, Badovinac VP, Griffith TS. CD4 T cell responses and the sepsis&#x2010;induced immunoparalysis State. Front Immunol. 2020; 11: 1364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7358556</ArticleId><ArticleId IdType="pubmed">32733454</ArticleId></ArticleIdList></Reference><Reference><Citation>Maucourant C, Filipovic I, Ponzetta A et&#xa0;al. Natural killer cell immunotypes related to COVID&#x2010;19 disease severity. Sci. Immunol. 2020; 5: eabd6832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7665314</ArticleId><ArticleId IdType="pubmed">32826343</ArticleId></ArticleIdList></Reference><Reference><Citation>Leem G, Cheon S, Lee H et&#xa0;al. Abnormality in the NK&#x2010;cell population is prolonged in severe COVID&#x2010;19 patients. J. Allergy Clin. Immunol. 2021; 148: 996&#x2013;1006.e18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8324384</ArticleId><ArticleId IdType="pubmed">34339730</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivier E, Tomasello E, Baratin M, Walzer T, Ugolini S. Functions of natural killer cells. Nat. Immunol. 2008; 9: 503&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">18425107</ArticleId></ArticleIdList></Reference><Reference><Citation>Romee R, Foley B, Lenvik T et&#xa0;al. NK cell CD16 surface expression and function is regulated by a disintegrin and metalloprotease&#x2010;17 (ADAM17). Blood 2013; 121: 3599&#x2013;608.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3643761</ArticleId><ArticleId IdType="pubmed">23487023</ArticleId></ArticleIdList></Reference><Reference><Citation>Bj&#xf6;rkstr&#xf6;m NK, Strunz B, Ljunggren HG. Natural killer cells in antiviral immunity. Nat. Rev. Immunol. 2022; 22: 112&#x2013;23. 10.1038/s41577-021-00558-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00558-3</ArticleId><ArticleId IdType="pmc">PMC8194386</ArticleId><ArticleId IdType="pubmed">34117484</ArticleId></ArticleIdList></Reference><Reference><Citation>Frere JJ, Serafini RA, Pryce KD et&#xa0;al. SARS&#x2010;CoV&#x2010;2 infection in hamsters and humans results in lasting and unique systemic perturbations post recovery. Sci. Transl. Med. 2022; 14: eabq3059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9210449</ArticleId><ArticleId IdType="pubmed">35857629</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>